CARGO Therapeutics Inc. - רווח נקי למניה ב-12 החודשים האחרונים CRGX

The resilience of the CARGO Therapeutics model is based on secured cryo-logistics for biomaterials, which minimizes raw material losses. The EPS YoY TTM growth trajectory confirms this stability, with the current value standing at . Price prospects depend on insurance regulation, while the primary drivers are the CRG-022 drug trials and the interest of major funds in proprietary cell production.
פילוחי מדדים פיננסיים ומדדי שוק עבור CARGO Therapeutics (CRGX)

Ultra-fast cryo-logistics for biomaterials require colossal capital expenditures, which directly impact the final profitability of CARGO Therapeutics (CRGX). The dynamics of these expenses determine the sensitivity of earnings per share to operating costs. This indicator measures the percentage change in the rolling 12-month annual profit. It allows for an assessment of business scaling efficiency through EPS growth rates. By analyzing the history of the YoY ttm net income per share growth rate, an investor can determine capital stability.